Omrix Biopharmaceuticals Ltd.

www.omrix.com

Now Omrix (Johnson & Johnson MedTech Biosurgery)

High-Tech Company

Acquired by Johnson & Johnson Inc.

TECH VERTICALS

Biotechnology, Life Sciences, MedTech, Therapeutics

General Data

Sector	Biomed
Company Stage:	Revenue Growth
Established	1995
Number of Employees	261

DESCRIPTION

Omrix is a fully integrated biopharmaceutical company that develops, manufactures and markets protein-based biosurgery and passive immunotherapy products. Omrix' biosurgery product line includes products and product candidates that are used for the control of bleeding, or hemostasis, and other surgical applications. The company's passive immunotherapy product line includes antibody-rich products and product candidates for the treatment of immune deficiencies, infectious diseases and potential biodefense applications.

TECHNOLOGY

Omrix currently manufactures and develops products in two areas: biosurgery and passive immunotherapy. While the end users are very different in these two areas of specialty, the company develops and commercializes all products through the use of its proprietary protein purification technology and manufacturing know-how.

Omrix proprietary protein purification technology is designed to purify proteins from plasma while maintaining their natural structure to preserve their full range of biological activities. The company can employ this technology on a commercial scale to either isolate proteins of interest or remove unwanted proteins from raw materials such as human plasma or plasma fractions.

Products and Phases

Product	Phase
Adhexil	Phase II
Prevention of adhesions in gynecology procedures
Aeris	Phase III
Minimally invasive lung volume reduction
EVICEL	FDA Approved
Evicel has the advantage of its ease of use, immediate availability to the surgeon and its bovine- and aprotinin-free formulation. It provides for important hemostasis support when conventional surgical techniques prove to be inefficient, ineffective or impractical.
Evithrom	FDA Approved
EVITHROM is a manufactured human plasma-derived alternative to the use of bovine protein-based thrombin, which is currently used to control bleeding in approximately one million surgical procedures each year in the United States. Exposure to bovine-derived thrombin has been shown to produce an immunogenic response in some patients. In patients who develop antibodies to bovine-derived thrombin there is an increased risk for complications including severe bleeding, thrombosis and anaphylactic shock. In addition, patients who develop antibodies to bovine-derived thrombin preparations are at a significantly higher risk of immunogenic response when re-exposed to these products.
Fibrin Patch	Phase II
Management of brisk bleeding and for use on active bleeding sites
Quixil	FDA Approved
Adjunct to Hemostasis for general surgical use
Thrombin	Phase III
Adjunct to Hemostasis for general surgical use, primarily neurosurgery

ESTIMATED ANNUAL SALES

Year	Amount
2007	500
2006	490
2005	480
2004	470
2003	460
2002	450
2001	440
2000	430

	TARGET MARKETS
	Hospitals, Medical Institutions.

	BUSINESS MODEL
	B2B

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Law Firm
abC Defghij	Investment Bank

REMARKS

Date	Remark
01/10/2008	Ethicon/Johnson & Johnson acquired Omri and turned it into its Israeli R&D center.

CONTACT INFO

Expand / Collapse All

Branch Address: Brussels, Belgium

Address	Ch de Waterloo 200, 1640 Rhode St Genese
City	Brussels
Country	Belgium
Zip	B-1180

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Ramat Gan, Israel

Address	MDA Blood Center, Tel Hashomer Hospital
City	Ramat Gan
Country	Israel
Zip	52621

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Main Address: New York, United States

Address	1120 Avenue of the Americas, 4th Floor
City	New York
State/Province	NY
Country	United States
Zip	10036

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address:


Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Mr. Robert Taub	Founder

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Acquired

Oct. 24, 2008

abCDe

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Dec. 15, 2006	Second Public Offering	NASDAQ GS	abCDe	abCDe	Including Green Shoe options ($10.8m)
Apr. 21, 2006	IPO	NASDAQ GS	abCDe	abCDe	Including Green Shoe options.

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Venture Lending

Mar. 31, 2005

Revenue Growth

abCDe

Other

Feb. 03, 2005

abCDe

Third Round

Jul. 01, 2004

Revenue Growth

abCDe

Internal Round

Jul. 01, 2002

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe	Holds 22.4% of the company
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe	Holds 15.9% of the company
abC Defghij	Other	abCDe	Feb. 2005: sold its holdings (4.2%) to Catalyst Fund for $1.63m

Second Round

Oct. 01, 2000

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe

First Round

Apr. 01, 1999

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Private Equity Fund	abCDe	Holds 6.1% of the company
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Dec. 10, 2006

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Bi-National Fund	abCDe	Co-op with Co-op with The BioSolutions Group (MA)

R&D Grant

Apr. 24, 2006

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Bi-Lateral R&D Program	abCDe	R&D grant
abC Defghij	Bi-Lateral R&D Program	abCDe	Granted by the EU Sixth Framework Program for R&D

R&D Grant

Jul. 28, 2003

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Other	abCDe	R&D grant ($3m)

Last Updated:	abCDe
IVC Number:	abCDe